Treatment-Resistant Depression Market to Rising at a CAGR of 15% Driven by Recent Advancements in Clinical Trials

LAS VEGAS, March 11, 2021 /PRNewswire/ — DelveInsight’s “Treatment-Resistant Depression (TRD) Market” report provides a thorough comprehension of the Treatment-Resistant Depression, historical and forecasted epidemiology, and the TRD market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan]. The Treatment-Resistant Depression market report also proffers an analysis of recent Treatment-Resistant Depression treatment algorithm/practice, market drivers, market barriers, and unmet medical needs. 

Some of the vital points of the Treatment-Resistant Depression Market Research Report

• The FDA approved SYMBYAX for acute treatment of TRD and depressive episodes associated with Bipolar Disorder in adults in March 2009. 
• In March 2019, the FDA approved Spravato-non-competitive N-methyl D-aspartate (NMDA) receptor antagonist, in conjunction with an oral antidepressant, for the TRD treatment in adults. It is the first-ever approved NMDA therapy for TRD. 
• Dominant players such as Eli Lilly and Company, Johnson& Johnson,  Janssen Pharmaceuticals, Axsome Therapeutics, Alkermes, Allergan/ Gedeon Richter, Minerva Neurosciences, Acadia Pharmaceuticals, Novartis, Celon Pharma, COMPASS Pathways, Relmada Therapeutics, Vistagen Therapeutics, OcuNexus Therapeutics, Eyevance Pharmaceuticals, and others involved in developing targeted TRD therapeutics.
• The Treatment-Resistant Depression market is expected to show positive growth, mainly attributed to an increased number of TRD cases and the expected launch of therapies such as AXS-05, ALKS-5461, Cariprazine, Seltorexant, Pimavanserin, MIJ821, Esketamine DPI, Psilocybin, REL-1017, and others.
• With a novel mechanism of action, these therapies may change the Treatment-Resistant Depression treatment regimen by 2030.

For further information on Market Impact by Therapies, visit: Treatment-Resistant Depression (TRD) Market Trends

Treatment-Resistant Depression (TRD) is a major depressive disorder (MDD) that does not respond to traditional and first-line therapeutic options. MDD is a mood disorder and causes a continuous feeling of sadness and loss of interest that can interfere with day-to-day life.

According to DelveInsight’s analysts, the total diagnosed Treatment-Resistant Depression prevalent population in 7MM was estimated to be 4,464,781 cases in 2017. The females appear to have a predisposition to Treatment-Resistant Depression, which is why a higher percentage of prevalence was observed in females than males in the United States.

The TRD Market Report provides historical as well as forecasted epidemiological analysis segmented into: 

• Total diagnosed prevalent cases 
• Gender-specific cases 
• Age-specific cases 

Get a sample copy of this report: Treatment-Resistant Depression Market Landscape

Treatment-Resistant Depression Treatment Market 

The TRD therapeutic market size is mainly regarded by the management options involving pharmacologic treatment options and non-pharmacological therapies. 

Pharmacologic treatment options comprise switching, combination, and potentiation strategy among the commonly used antidepressant drugs. The majority of the available antidepressants such as Selective Serotonin Reuptake Inhibitor (SSRI), Dual serotonin and norepinephrine reuptake inhibitors (SNRIs), Tricyclic antidepressant, Irreversible, non-selective monoamine oxidase inhibitors (MAOIs), α2-antagonists, Agomelatine, Tianeptine are used for Treatment-Resistant Depression Treatment.

Switching is recommended when there is no response or low tolerance to the initial treatment, inadequate response to the newly introduced treatment. Selective Serotonin Reuptake Inhibitor (SSRI) is considered a first-line treatment, nevertheless of the clinical severity. When there is no response from SSRI, norepinephrine reuptake inhibitors (SNRIs) are taken into consideration. But, there is no response from SNRIs; the next approach is a tricyclic antidepressant. 

The combination strategy is only recommended in partial response cases after 4 to 6 weeks of adequate treatment. In the first-line, the recommended strategies comprise combinations such as SSRI + α2 antagonist, SNRI + α2 antagonist, and Tricyclic antidepressant + α2-antagonist. In the second-line treatment, an association between SSRIs, SNRIs, or tricyclic antidepressants and agomelatine can be proposed.

Non-pharmacological therapies involve electroconvulsive therapy (ECT), Repetitive transcranial magnetic stimulation (rTMS), and Vagus nerve stimulation (VNS). Along with this, two alternative forms of psychotherapy comprise majorly cognitive-behavioural therapy (CBT) and interpersonal therapy (IPT).

Despite an increasing variety of choices for the treatment of TRD, this condition continues to be universally undefined and represents an area of unmet medical need. There are only a few known approved TRD pharmacological agents. So, various biotechnological companies are working towards the development of targeted TRD therapeutics. 

TRD Emerging Therapies Along with Key Players 

• ALKS 5461: Alkermes
• Cariprazine: Allergan/Gedeon Richter
• Pimavanserin: ACADIA Pharmaceuticals
• AXS-05: Axsome Therapeutics
• Seltorexant: Johnson and Johnson/Minerva Neurosciences
• Esketamine DPI: Celon Pharma
• REL-1017: Relmada Therapeutics
• AV-101: VistaGen Therapeutics
• MIJ821: Novartis
• Psilocybin (COMP360): COMPASS Pathways

And several others.

Final comments on Treatment-Resistant Depression Market Growth 

Treatment-Resistant Depression Market Drivers 

• Research and Development – Increase in the understanding of pathophysiology and the development of novel therapeutic compounds have emerged.
• Development of Pioneering Therapies – Various drugs are in the trial that can help in the growth of the TRD market in the future. Next-generation SSRI antidepressants are being developed with the promise of better tolerability. Demand for the new antidepressant agents leads to an increase in research activities, and researchers are focusing on the various targets such as NMDA and others.
• Retainment of Current Management Strategies and Refined Clinical Trial Design 

Treatment-Resistant Depression Market Barriers 

• Economic Burden – The burden of depression is increasing despite advancements in treatments. Several factors contribute to the economic burden, including the prevalence, rate, degree of impairment, and lesser remission.
• Variable Treatment Response – The disease is itself treatment-resistant which encourages increasingly risky treatment interventions that are likely to affect patients negatively Treatment options are limited and also with increased toxicity with higher dosages and combination regimens.
• Commercial Challenges – Stringent policies for regulatory approvals can be a threat to the TRD market. Gaining market access and reimbursement further complicates it.

Scope of the Treatment-Resistant Depression Market Insight Report 

• Geography Covered: 7MM – The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
• Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).
• Treatment-Resistant Depression Markets Segmentation: By Geographies and By Treatment-Resistant Depression Therapies (Historical and Forecasted, Current and Upcoming) 
• Dominant Market Companies investigating its candidates for Treatment-Resistant Depression: Eli Lilly and Company, Johnson& Johnson,  Janssen Pharmaceuticals, Axsome Therapeutics, Alkermes, Allergan/ Gedeon Richter, Minerva Neurosciences, Acadia Pharmaceuticals, Novartis, Celon Pharma, COMPASS Pathways, Relmada Therapeutics, Vistagen Therapeutics, OcuNexus Therapeutics, Eyevance Pharmaceuticals, and several others.
• Analysis: Comparative and conjoint analysis of emerging therapies.
• Case Studies
• KOL’s Views
• Analyst’s View

Request for a Webex demo of the report @ TRD Treatment Market Size

Table of Contents 

Browse full report with detailed TOC with charts, figures, tables @ Treatment-Resistant Depression Market Size Report 

View Related Reports       

DelveInsight’s Treatment-resistant depression – Epidemiology Forecast 2030 report delivers an in-depth understanding of the historical, and forecasted epidemiology of the disease in 7MM.

Treatment-Resistant Depression Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Treatment-Resistant Depression market.

DelveInsight’s Bipolar Disorder (Manic Depression) – Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed overview of the disease and in-depth understanding.

DelveInsight’s Postpartum Depression – Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed overview of the disease and in-depth understanding.

Bipolar Disorder (Manic Depression) – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 ” report by DelveInsight offers comprehensive insights on marketed and Phase III products for Bipolar Disorder (Manic Depression).

DelveInsight’s Major Depressive Disorder – Market Insights, Epidemiology, and Market Forecast – 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.

VCF Treatment Devices Market Insights, Competitive Landscape and Market Forecast-2025 report delivers an in-depth understanding of VCF Treatment Devices. 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Contact Us:

Shruti Thakur 
[email protected] 
+1(919)321-6187 
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP